Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiganle capsules are a traditional Chinese medicine (TCM) formulation primarily used for hepatoprotection and liver support. The active ingredient is typically gypenosides, which are saponins extracted from the plant *Gynostemma pentaphyllum*. The medication is indicated for the treatment of chronic hepatitis, fatty liver, and toxic liver injury, specifically to help reduce elevated transaminase levels and improve overall liver function. Its mechanism of action involves stabilizing hepatocyte membranes, reducing oxidative stress through free radical scavenging, and promoting protein synthesis within liver cells to aid regeneration. While Shuangren Pharmaceutical is associated with the distribution of this product, it is a widely available Chinese patent medicine produced by various manufacturers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiganle capsules.